BioSpace News Archive

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that the Food and Drug Administration has provided 510(k) market clearance for the PROLIFT Lateral Expandable Spacer System.

Cohen Children’s Medical Center has earned top 50 national rankings for exceptional care in nine pediatric specialties, according to US News & World Report’s 2019-2020 Best Children’s Hospitals.

AlloSource®, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, today announced it is now part of a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI).

Silicon Valley-based Medable Inc. continues to disrupt clinical trials with the first telemedicine solution, specifically designed for clinical trials

For the fourth time since 2000, Chambers USA highlights Firm’s excellence in healthcare client service and its pursuit of innovation

Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education, announces the full agenda for the 20th Annual International Lung Cancer Congress®.

Ajax Health announced today that it has raised an additional $15 million, closing out Ajax II at a total of more than $100 million.

The Stepping Stones Group announced the acquisition of StaffRehab, a California based provider of therapy, nursing, and behavioral health services to children with autism and special needs in school settings.

Signant Health (formerly CRF Health and Bracket) will provide expert insights at the forthcoming DIA Global Annual Meeting in San Diego, CA., from 23-27 June 2019.

Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that the Biomedical Advanced Research and Development Authority (‘BARDA’) has increased the total value of its award for the clinical and regulatory development of Summit’s precision antibiotic ridinilazole for the treatment of C. difficile infection (‘CDI’) to up to $63.7 million.